Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients
Authors:
- Kevin DidierKDKevin Didier
- Vincent SobanskiVSVincent Sobanski
- Ailsa RobbinsARAilsa Robbins
- Marie-Elise TruchetetMTMarie-Elise Truchetet
- Thomas BarnetcheTBThomas Barnetche
- Cécile Contin-BordesCCCécile Contin-Bordes
- Arnaud HotAHArnaud Hot
- Romain FortRFRomain Fort
- Philippe GuilpainPGPhilippe Guilpain
- Alexandre MariaAMAlexandre Maria
- Christian AgardCAChristian Agard
- Jean-Loup PennaforteJPJean-Loup Pennaforte
Open Access
Abstract
Introduction Systemic sclerosis (SSc) is a rare autoimmune disease currently classified into two subgroups based on skin extension. The aim of this study was to determine in a large cohort whether the determination of autoantibody (AAb) profile among a full antinuclear AAbs panel including nine specificities had a higher impact than skin phenotype on stratifying the risk of organ involvement and mortality in SSc. Methods Data for patients with SSc followed in seven French university hospitals were retrospectively analysed in terms of skin phenotype, AAbs (anti-topoisomerase I (ATA), anticentromere (ACA), anti-RNA polymerase III (anti-RNAPIII), anti-U1RNP, anti-U3RNP, anti-Pm/Scl, anti-Ku, anti-Th/To, anti-NOR90), organ involvement and mortality. Multivariate analyses were performed to identify independent factors associated with organ involvement and mortality. Results We included 1605 patients with SSc (367 with diffuse cutaneous SSc). On multivariate analysis, ATAs were associated with interstitial lung disease and mortality (OR=3.27 (95% CI 2.42 to 4.42); HR=1.9 (95% CI 1.01 to 3.58)), anti-RNAPIII with scleroderma renal crisis and mortality (OR=7.05 (95% CI 2.98 to 16.72); HR=2.35 (95% CI 1.12 to 4.93)), anti-U1RNP with arthritis (OR=3.79 (95% CI 2.16 to 6.67)), anti-Pm/Scl and anti-Ku with myositis (OR=7.09 (95% CI 3.87 to 12.98) and 7.99 (95% CI 2.41 to 26.46)). The skin phenotype was not associated with survival or organ involvement on multivariate analysis without stepwise selection. Conclusion This study unravels, by contrast with skin phenotype, a strong association between AAbs specificities, organ involvement and outcome in SSc and suggests that patients’ classification based on only skin extension is not sufficient for defining prognosis and phenotype.Keywords
This publication has 51 references indexed in Scilit:
- Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical featuresArthritis Research & Therapy, 2011
- Anti-centromere antibodies in a large cohort of systemic sclerosis patients: Comparison between immunofluorescence, CENP-A and CENP-B ELISAClinica Chimica Acta, 2011
- Anti–U3 RNP autoantibodies in systemic sclerosisArthritis & Rheumatism, 2009
- Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study.2007
- Evaluation of the BioPlex 2200 ANA Screen for the Detection of Antinuclear Antibodies and Comparison with Conventional MethodsAnnals of the New York Academy of Sciences, 2007
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Laboratory screening of connective tissue diseases by a new automated ENA screening assay (EliA Symphony) in clinically defined patientsClinica Chimica Acta, 2005
- Autoantibodies in Systemic SclerosisSeminars in Arthritis and Rheumatism, 2005
- Criteria for the classification of early systemic sclerosis.2001
- Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic SclerosisArthritis & Rheumatism, 1994